Personalizing the duration of androgen-deprivation therapy use in the management of intermediate-risk prostate cancer

Journal of Clinical Oncology

Volumn 33, Issue 4, 2015, Pages 301-303

  D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANCER RADIOTHERAPY; EDITORIAL; HUMAN; MALE; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT DURATION; TREATMENT INDICATION; PROCEDURES; PROSTATIC NEOPLASMS; RADIOTHERAPY;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 84921914182     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.0968     Document Type: Editorial

References (19)

1. Mohler JL, Kantoff PW, Armstrong AJ, et al: Prostate cancer, version 1.2014. J Natl Compr Canc Netw 11: 1471-1479, 2013
2. D'Amico AV, Moul J, Carroll PR, et al: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21: 2163-2172, 2003
3. Mitchell JA, Cooperberg MR, Elkin EP, et al: Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. J Urol 173: 1126-1131, 2005
4. Freedland SJ, Aronson WJ, Terris MK, et al: Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: Results from SEARCH database. J Urol 169: 2136-2141, 2003
5. D'Amico AV, Whittington R, Malkowicz SB, et al: Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18: 1164-1172, 2000
6. D'Amico AV, Renshaw AA, Cote K, et al: Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 22: 3726-3732, 2004
7. Antunes AA, Srougi M, Dall'Oglio MF, et al: The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy. BJU Int 96: 1258-1263, 2005
8. Nguyen PL, Chen MH, Catalona WJ, et al: Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 73: 659-664, 2009
9. Helpap B, Ringli D, Shaikhibrahim Z, et al: The heterogeneous Gleason 7 carcinoma of the prostate: Analyses of low and high grade (risk) carcinomas with criteria of the International Society of Urological Pathology (ISUP). Pathol Res Pract 209: 190-194, 2013
10. Zumsteg ZS, Spratt DE, Pei I, et al: A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64: 895-902, 2013
11. Jones CU, Hunt D, McGowan DG, et al: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365: 107-118, 2011
12. Denham JW, Steigler A, Lamb DS, et al: Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12: 451-459, 2011
13. D'Amico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292: 821-827, 2004
14. Castle KO, Hoffman KE, Levy LB, et al: Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys 85: 693-699, 2013
15. Keane FK, Chen M-H, Zhang D, et al: The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer 120: 1787-1793, 2014
16. Pisansky TM, Hunt D, Gomella LG, et al: Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation Therapy Oncology Group randomized clinical trial 9910. J Clin Oncol 33: 332-339, 2015
17. Zapatero A, Guerrero A, Maldonado, et al: Randomized phase 3 trial of adjvant androgen deprivation in combination with high dose conformal radiation therapy in interemediate- and high-risk prostate cancer. Int J Rad Oncol 90: S1, 2014 (abstr PL-02)
18. Michalski J, Moughan J, Purdy J, et al: Initial results of a phase III randomized study of high dose 3DCRT/IMRT versus standard dose 3D-CRT/IMRT in men with localized prostate cancer. Int J Rad Oncol 90: S1, 2014 (abstr PL-03)
19. Daskivich TJ, Fan KH, Koyama T, et al: Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 158: 709-717, 2013